MedPath

comparison of two supraglottic airway devices

Recruiting
Conditions
symptomatic patients of cholecystitis undergoing laparoscopic cholecystectomy
Registration Number
CTRI/2017/05/008671
Lead Sponsor
Dr RPGMCTanda
Brief Summary

Intubationof trachea using a tracheal tube requires high skill levels, continuoustraining and frequent practice1.The laryngeal mask airway(LMA)  maybe used to provide a routine airway for use during general anaesthesia or lessfrequently as a conduit for tracheal intubation2.In case ofthe anticipated and unanticipated difficult airway the supraglottic airway havea special place in the difficult airway algorithm3. Since theintroduction of the Laryngeal Mask Airway Classic(LMA-C), several othersupraglotticdevices with improved designs  have been introduced in order to improveefficacy and safety.

Thesedesigns offer a cuff that allows a higher seal pressure than the LMA-C and adrain tube that allows venting of the stomach contents and blind insertion ofstandard gastric tubes4. Therefore, these new generation LMAsprovides certain protection against regurgitation and prevent gastric insuffulationwhen correctly placed. These devices are a reasonable choice when performinganesthesia for procedures accompanied by high peak airway pressure, such aslaparoscopic cholecystectomy5.

I-gel is a second generation supraglottic airway, made of a medical gradethermoplastic elastomer, designed to create a non-inflatable anatomical seal ofthe pharyngeal, laryngeal and peri-laryngeal structures.I-gel  is easy and reliable to insert and is idealfor use as a routine airway in anaesthesia as it provides high seal pressuresand reduced trauma. An integrated gastric channel provides an early warning ofregurgitation, facilitates venting of gas from the stomach and allows for thepassing of a suction tube to empty the stomach contents to provide additionalprotection against aspiration and has the versatility to be applicable for useduring difficult airway management, as a rescue device and a conduit for intubation(with fibreoptic guidance).

The Baska mask is a  supraglottic airway with high volume suctionclearance. The Baska mask is a new supraglottic airway device, featuringnon-inflatable cuff that may facilitate a better airway seal, seal increaseswith IPPV without gastric inflation and novel pharyngeal drainage system thatmay reduce the risk of lung aspiration, and integrated bite block.

Till date,no randomized study has been undertaken to judge its sealing pressure ascompared to i-gel. We hypothesized that with its cuffless membranous bowl; thebaska mask would withstand higher inflation pressures, have a faster placementtime, and have no problem with diffusion of nitrous oxide despite longerduration of use that would lead to less postoperative laryngopharyngealmorbidity as compared to i-gel in patients undergoing elective surgicalprocedures of 2 hours or less duration.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
80
Inclusion Criteria

1.American Society of Anesthesiologists physical status score I or II 2.20 -70 yr old patient of either sex 3.Surgery time of less than 2 hr 4.An elective laparoscopic cholecystectomy.

Exclusion Criteria

1.A known or predicted difficult airway 2.A mouth opening of <2.5 cm 3.Increased risk of aspiration of gastric contents 4.Any pathology of neck or upper respiratory tract 5.Obesity (body mass index > 30 Kg/ m2).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Success and ease of insertion, insertion time and air leak test of baska mask vs IgelAt the time point of securing airway and for next 5 minutes after securing airway, air leak pressures and leak fraction every 30min.till the end of surgery
Secondary Outcome Measures
NameTimeMethod
Ease of removal and post operative airway morbidity in form of sore throat, dysphonia, dysphagiaAt the time of extubation at end of surgery and at 1 hour and two hours of removal of airway device.

Trial Locations

Locations (1)

Dr. RPGMC,Tanda, Kangra,HP

🇮🇳

Kangra, HIMACHAL PRADESH, India

Dr. RPGMC,Tanda, Kangra,HP
🇮🇳Kangra, HIMACHAL PRADESH, India
Dr Monika Mahajan
Principal investigator
9781484200
mon.mahajan@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.